ABOUT DASH BIO
Dash Bio is a CRO on a mission to accelerate the process by which drugs are developed. Traditional bioanalysis is slow, manual and error‑prone. Dash changes the equation as the only tech-first bioanalysis partner, putting both speed and quality at the forefront. Processing every sample on an automated platform, they eliminate variability and delays, delivering high quality, GLP-compliant results for preclinical and clinical studies in days, not months. Dash provides ELISA/MSD, LC‑MS and qPCR assays across a wide range of biomatrices, sample prep methods and customization options, enabling sponsors to move from insight to action, faster. Co-founded by industry veterans who understand the pain of the traditional CRO model, Dash's model prioritizes transparency, publishing pricing upfront and backing every project with guaranteed timelines and outcomes.
FEATURED ARTICLES
-
![GettyImages-506999858-scientists-cell-culture-lab-development]( "Building Bioanalysis Infrastructure For Modern Drug Development")
Drug development accelerates with AI, decentralized trials, and adaptive protocols, but legacy CRO infrastructure lags. Platform-based systems enable speed, quality, automation, and continuous improvement.
-
![GettyImages-1183908006 bioanalysis]( "5 Outdated Practices Holding Back Modern Bioanalysis")
Bioanalysis must replace outdated paper, manual processes, and disjointed systems with integrated, automated platforms for continuous validation, efficiency, compliance, and to support complex modern therapies.
-
![GettyImages-462287059-computer-motherboard]( "Built Like A Tech Company: Why CROs Need A New Operating System")
See why building digital, automated infrastructure is essential, and better aligns CROs with today's speed, compliance, and innovation needs.
-
![GettyImages-871431000 doctor partner]( "Five Questions Biotechs Should Ask Before Selecting A Bioanalytical CRO")
In a landscape where speed, quality, and trust are inseparable, choosing a CRO that shares your ambition is not optional; it is essential to survival and success.
-
![GettyImages-2158124620-scientist-laboratory-containers-testing-analysis]( "Accelerating IND-Enabling Studies With Automated Bioanalysis Workflows")
Reimagined as automation-first, bioanalysis shifts from being an Investigational New Drug (IND) bottleneck to a catalyst for innovation—helping companies move therapies forward with greater confidence.
-
![exam, test, analysis, innovation, development-GettyImages-2149039471]( "Why Bioanalysis Needs To Break Free From Manual Bottlenecks")
Bioanalysis remains one of the most persistent bottlenecks in drug development, with CROs displaying inefficiencies that are no longer operational nuisances but strategic liabilities.
CONTACT INFORMATION
Dash Bio
56 Broad St STE 14011
Boston, MA 02109
UNITED STATES
Phone: 617-249-4472
Contact: Ander Tallett